CVS Health Corp
CVS: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$47.00 | Fjjnd | Gdmfrlwn |
CVS Earnings: Management Pulls Intermediate Targets, Despite Decent Trends and 2023 Outlook
Narrow-moat CVS Health delivered solid second-quarter results and maintained its 2023 outlook but reduced its 2024 and 2025 goals. Slight changes to our intermediate-term assumptions, which were already below management's previous targets, do not materially change our $113 fair value estimate, though. CVS shares remain significantly undervalued, in our view.